Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

namodenoson

An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:A3AdR agonist CF102
adenosine receptor A3 agonist CF102
Abbreviation:2-Cl-IB-MECA
C-Ibza-MU
Code name:CF102
Chemical structure:2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
beta-D-ribofuranuronamide, 1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search